

Special Issue

Urogenital Cancers: New Molecular and Translational Aspects on Carcinogenesis and Treatments

Message from the Guest Editors

We are pleased to invite you to submit a manuscript to the Special Issue “Urogenital Cancers: New Molecular and Translational Aspects on Carcinogenesis and Treatments”. Most types of urogenital cancer present with non-specific symptoms and the arrival of the diagnosis is often late. Despite progress in the most innovative tumor therapies, the appearance of chemoresistance and metastasis represents a common cause of death in patients suffering from urological neoplasms. Therefore, it is necessary to develop new early diagnosis approaches and therapies that can improve treatment outcomes. For this purpose, it seems important to implement an understanding of the molecular mechanisms that occur in urological tumors and the research on molecular biomarkers capable of predicting tumor behavior and the risk of disease recurrence and chemoresistance. The main aim of this Special Issue is to publish original research articles and reviews relating to urological neoplasms. We look forward to receiving your contributions.

Guest Editors

Dr. Silvia Di Agostino
Dr. Vittoria Rago
Dr. Anna Perri

Deadline for manuscript submissions

closed (31 March 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/199481

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).